☰

Robert J. DeVita - Publications

Affiliations: 
Pharmacology Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Leandro J, Khamrui S, Suebsuwong C, Chen PJ, Secor C, Dodatko T, Yu C, Sanchez R, DeVita RJ, Houten SM, Lazarus MB. Characterization and structure of the human lysine-2-oxoglutarate reductase domain, a novel therapeutic target for treatment of glutaric aciduria type 1. Open Biology. 12: 220179. PMID 36128717 DOI: 10.1098/rsob.220179  0.737
2021 Wang P, Karakose E, Choleva L, Kumar K, DeVita RJ, Garcia-Ocaña A, Stewart AF. Human Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges. Frontiers in Endocrinology. 12: 671946. PMID 34335466 DOI: 10.3389/fendo.2021.671946  0.61
2021 He Z, Chen L, Catalan-Dibene J, Bongers G, Faith JJ, Suebsuwong C, DeVita RJ, Shen Z, Fox JG, Lafaille JJ, Furtado GC, Lira SA. Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23. Cell Metabolism. PMID 33989521 DOI: 10.1016/j.cmet.2021.04.015  0.693
2021 Kumar K, Suebsuwong C, Wang P, Garcia-Ocana A, Stewart AF, DeVita RJ. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes. Journal of Medicinal Chemistry. PMID 33682417 DOI: 10.1021/acs.jmedchem.0c02050  0.715
2021 Wu K, Huynh KQ, Lu I, Moustakim M, Miao H, Yu C, Haeusgen MJ, Hopkins BD, Huang L, Zheng N, Sanchez R, DeVita RJ, Pan ZQ. Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33602808 DOI: 10.1073/pnas.2007328118  0.725
2020 Leandro J, Khamrui S, Wang H, Suebsuwong C, Nemeria NS, Huynh K, Moustakim M, Secor C, Wang M, Dodatko T, Stauffer B, Wilson CG, Yu C, Arkin MR, Jordan F, ... ... DeVita RJ, et al. Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex. Acs Chemical Biology. PMID 32633484 DOI: 10.1021/Acschembio.0C00114  0.648
2020 Kumar K, Wang P, A Swartz E, Khamrui S, Secor C, B Lazarus M, Sanchez R, F Stewart A, DeVita RJ. Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation. Molecules (Basel, Switzerland). 25. PMID 32340326 DOI: 10.3390/Molecules25081983  0.701
2020 Leandro J, Dodatko T, Aten J, Nemeria NS, Zhang X, Jordan F, Hendrickson RC, Sanchez R, Yu C, DeVita RJ, Houten SM. DHTKD1 and OGDH display substrate overlap in cultured cells and form a hybrid 2-oxo acid dehydrogenase complex in vivo. Human Molecular Genetics. PMID 32160276 DOI: 10.1093/Hmg/Ddaa037  0.35
2020 Ackeifi C, Wang P, Karakose E, Manning Fox JE, González BJ, Liu H, Wilson J, Swartz E, Berrouet C, Li Y, Kumar K, MacDonald PE, Sanchez R, Thorens B, DeVita R, et al. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Science Translational Medicine. 12. PMID 32051230 DOI: 10.1126/Scitranslmed.Aaw9996  0.693
2020 Kumar K, Wang P, Wilson J, Zlatanic V, Berrouet C, Khamrui S, Secor C, Swartz E, Lazarus MB, Sanchez R, Stewart AF, Garcia-Ocana A, DeVita RJ. Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor. Journal of Medicinal Chemistry. PMID 32003560 DOI: 10.1021/Acs.Jmedchem.9B01379  0.704
2019 Ackeifi C, Swartz E, Kumar K, Liu H, Chalada S, Karakose E, Scott DK, Garcia-Ocaña A, Sanchez R, DeVita RJ, Stewart AF, Wang P. Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors. Jci Insight. PMID 31821176 DOI: 10.1172/Jci.Insight.132594  0.651
2019 Ung PM, DeVita RJ, Schlessinger A. Encounter and React: Computer-Guided Design of Covalent Inhibitors. Cell Chemical Biology. 26: 6-8. PMID 30658111 DOI: 10.1016/J.Chembiol.2018.12.009  0.358
2018 Kumar K, Man-Un Ung P, Wang P, Wang H, Li H, Andrews MK, Stewart AF, Schlessinger A, DeVita RJ. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. European Journal of Medicinal Chemistry. 157: 1005-1016. PMID 30170319 DOI: 10.1016/J.Ejmech.2018.08.007  0.747
2018 Kumar K, Wang P, Sanchez R, Swartz E, Stewart AF, DeVita RJ. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation. Journal of Medicinal Chemistry. PMID 30059217 DOI: 10.1021/Acs.Jmedchem.8B00658  0.701
2018 Chang CJ, Kotini AG, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, Sanchez R, DeVita R, Martins TJ, Abdel-Wahab O, Bradley RK, Papapetrou EP. Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports. PMID 29681544 DOI: 10.1016/J.Stemcr.2018.03.020  0.332
2010 Howell KL, DeVita RJ, Garcia-Calvo M, Meurer RD, Lisnock J, Bull HG, McMasters DR, McCann ME, Mills SG. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy. Bioorganic & Medicinal Chemistry Letters. 20: 6929-32. PMID 21030254 DOI: 10.1016/j.bmcl.2010.09.138  0.301
Show low-probability matches.